Related references
Note: Only part of the references are listed.Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells
Silvana Cianchetti et al.
ATHEROSCLEROSIS (2008)
Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization
Ruth E. Hogg et al.
OPHTHALMOLOGY (2008)
Peroxisome proliferator-activated receptor-γ ligands as investigational modulators of angiogenesis
Costas Giaginis et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials
Rodrigo M. Lago et al.
LANCET (2007)
Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes
Tetsuya Sugiyama et al.
EXPERIMENTAL EYE RESEARCH (2007)
Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-κB pathway
Norihiro Nagai et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2007)
Management of diabetic retinopathy - A systematic review
Quresh Mohamed et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker
Jing Shao et al.
JOURNAL OF HYPERTENSION (2007)
Pioglitazone:: update on an oral antidiabetic drug with antiatherosclerotic effects
Andreas Pfuetzner et al.
EXPERT OPINION ON PHARMACOTHERAPY (2007)
How the diabetic eye loses vision
Jaime A. Davidson et al.
ENDOCRINE (2007)
Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis
Philip D. Home et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Prevention of hypertension abrogates early inflammatory events in the retina of diabetic hypertensive rats
Kamila C. Silva et al.
EXPERIMENTAL EYE RESEARCH (2007)
Angiotensin II and its receptor subtypes in the human retina
Preenie deS. Senanayake et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone
G. Derosa et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2007)
Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: Minimal role of bradykinin
Norihiro Nagai et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2007)
Drug delivery methods for posterior segment disease
Jason Hsu
CURRENT OPINION IN OPHTHALMOLOGY (2007)
The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction - Results from the PROactive (PROactive 05) study
Erland Erdmann et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Valsartan but not Atenolol improves vascular pathology in diabetic Ren-2 rat retina
Jennifer Louise Wilkinson-Berka et al.
AMERICAN JOURNAL OF HYPERTENSION (2007)
Retinal dysfunction in diabetic Ren-2 rats is ameliorated by treatment with valsartan but not atenolol
Joanna A. Phipps et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2007)
Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors
Philippe Gervois et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2007)
Arterial hypertension exacerbates oxidative stress in early diabetic retinopathy
Camila C. Pinto et al.
FREE RADICAL RESEARCH (2007)
Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects
Fang Zhang et al.
PPAR RESEARCH (2007)
Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema
M. Vaughn Emerson et al.
BIODRUGS (2007)
Overview of epidemiologic studies of diabetic retinopathy
Barbara Eden Kobrin Klein
OPHTHALMIC EPIDEMIOLOGY (2007)
Ocular neovascularization: Basic mechanisms and therapeutic advances
Michael Dorrell et al.
SURVEY OF OPHTHALMOLOGY (2007)
Emerging therapies for Neovascular age-related macular degeneration: State of the art
Guy Donati
OPHTHALMOLOGICA (2007)
Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation
Toshihide Kurihara et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2006)
Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease
James Varani et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2006)
Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone:: Effects on insulin-resistance, leptin and tumor necrosis factor-α
Giuseppe Derosa et al.
HYPERTENSION RESEARCH (2006)
Role of angiotensin II in retinal leukostasis in the diabetic rat
Ping Chen et al.
EXPERIMENTAL EYE RESEARCH (2006)
Effects of peroxisome proliferator-activated receptor γ and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model
Kimimasa Muranaka et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2006)
Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization
Norihiro Nagai et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor γ
Ikuyo Imayama et al.
CARDIOVASCULAR RESEARCH (2006)
Age-related macular degeneration: A practical approach to a challenging disease
Dan H. Bourla et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2006)
Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications
Rhian M. Touyz et al.
VASCULAR PHARMACOLOGY (2006)
Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis
K Sugimoto et al.
HYPERTENSION (2006)
Diabetic macular edema associated with glitazone use
Edwin H. Ryan et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2006)
Involvement of PPAR nuclear receptors in tissue injury and wound repair
L Michalik et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond
Allen Clermont et al.
JOURNAL OF HYPERTENSION (2006)
Angiotensin and diabetic retinopathy
JL Wilkinson-Berka
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2006)
Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma
HA Pershadsingh
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2006)
Recent progress in ocular drug delivery for posterior segment disease: Emphasis on transscleral iontophoresis
ME Myles et al.
ADVANCED DRUG DELIVERY REVIEWS (2005)
Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity
M Schupp et al.
DIABETES (2005)
Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone - A preliminary study
GS Watson et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus
M Colucciello
ARCHIVES OF OPHTHALMOLOGY (2005)
Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression
S Yamagishi et al.
FEBS LETTERS (2005)
Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator
TW Kurtz
ACTA DIABETOLOGICA (2005)
Angiogenesis: a curse or cure?
K Gupta et al.
POSTGRADUATE MEDICAL JOURNAL (2005)
Pericytes and the pathogenesis of diabetic retinopathy
HP Hammes
HORMONE AND METABOLIC RESEARCH (2005)
Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-γ ligand
MA Sarayba et al.
EXPERIMENTAL EYE RESEARCH (2005)
The renin-angiotensin system and the developing retinal vasculature
S Sarlos et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2005)
Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor
N Nagai et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2005)
PPARs in diseases: Control mechanisms of inflammation
R Kostadinova et al.
CURRENT MEDICINAL CHEMISTRY (2005)
Current concepts in the pathogenesis of age-related macular degeneration
MA Zarbin
ARCHIVES OF OPHTHALMOLOGY (2004)
Pleiotropic effects of thiazolidinediones: Taking a look beyond antidiabetic activity
S Giannini et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2004)
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-α activity
M Schupp et al.
CIRCULATION (2004)
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity
SC Benson et al.
HYPERTENSION (2004)
Role of growth factors and the wound healing response in age-related macular degeneration
RO Schlingemann
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2004)
Thiazolidinedione use, fluid retention, and congestive heart failure - A consensus statement from the American Heart Association and American Diabetes Association
RW Nesto et al.
CIRCULATION (2003)
Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: The Rotterdam Study
R van Leeuwen et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2003)
Diabetic retinopathy and diabetic macular edema - Pathophysiology, screening, and novel therapies
TA Ciulla et al.
DIABETES CARE (2003)
Role of PPAR-γ ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells
P Aoun et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2003)
Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator
JP Berger et al.
MOLECULAR ENDOCRINOLOGY (2003)
Minireview: Nuclear receptor coactivators - An update
NJ McKenna et al.
ENDOCRINOLOGY (2002)
Genetic analysis of four novel peroxisome proliferator activated receptor-γ splice variants in monkey macrophages
JM Zhou et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Effects of angiogenic growth factor combinations on retinal endothelial cells
R Castellon et al.
EXPERIMENTAL EYE RESEARCH (2002)
Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy
H Funatsu et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2002)
Transscleral drug delivery for posterior segment disease
DH Geroski et al.
ADVANCED DRUG DELIVERY REVIEWS (2001)
Comparison of angiotensin II receptor antagonists
W Kirch et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2001)
Potential roles of the peroxisome proliferator-activated receptor-γ in macrophage biology and atherosclerosis
CK Glass
JOURNAL OF ENDOCRINOLOGY (2001)
Peroxisome proliferator-activated receptors in inflammation control
P Delerive et al.
JOURNAL OF ENDOCRINOLOGY (2001)
Response of experimental retinal neovascularization to thiazolidinediones
T Murata et al.
ARCHIVES OF OPHTHALMOLOGY (2001)
The pleiotropic functions of peroxisome proliferator-activated receptor gamma
MB Debril et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2001)
The PPARs: From orphan receptors to drug discovery
TM Willson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
